Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.
CITATION STYLE
Storz, U. (2016). Intellectual property issues of immune checkpoint inhibitors. MAbs, 8(1), 10–26. https://doi.org/10.1080/19420862.2015.1107688
Mendeley helps you to discover research relevant for your work.